Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
about
Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerOsimertinib making a breakthrough in lung cancer targeted therapyOne reporter for in-cell activity profiling of majority of protein kinase oncogenes.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants.[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Structural insights into drug development strategy targeting EGFR T790M/C797S.First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsDiscovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant InhibitorCombining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer
P2860
Q28075704-CC8D3752-3B0A-4A7A-B12D-65F0478BD773Q28079689-CBD569F1-72DA-4CAE-8FBE-E06ABD5B85D0Q37643703-2F333D91-6294-4C1D-8A77-BD984CD41875Q38729111-51BEC713-423D-4164-A76E-70EE8E565940Q38838227-1DC06FEB-F38D-4E19-9A4B-10336E165A9BQ42279529-D52D4F44-0597-4E35-A204-52D297E2614FQ47719484-62E29129-D069-45EE-9984-19ACBF604229Q50545253-81878263-CAFD-4026-AE8D-E92E4AD88601Q50794518-B4749A89-8946-4097-A008-75647A16F0CAQ52345422-3798F82E-2F6C-4A85-905F-885B1CA6BA28Q52611428-6B54EB53-AC3A-4E82-B5FB-C9F6EDAD4987Q55410133-37150042-2582-41C1-9D5F-F5C1F24E98ADQ58599659-1E575CF0-D01E-4508-B2B7-BE2FF02671F9Q58801031-66CFE38A-F113-49DE-A63B-CE530F18EB30Q59125278-3D449CCE-DA42-4D12-B8C7-7ECC730AE8CA
P2860
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Binding mode of the breakthrou ...... rowth factor receptor revealed
@ast
Binding mode of the breakthrou ...... rowth factor receptor revealed
@en
Binding mode of the breakthrou ...... rowth factor receptor revealed
@nl
type
label
Binding mode of the breakthrou ...... rowth factor receptor revealed
@ast
Binding mode of the breakthrou ...... rowth factor receptor revealed
@en
Binding mode of the breakthrou ...... rowth factor receptor revealed
@nl
prefLabel
Binding mode of the breakthrou ...... rowth factor receptor revealed
@ast
Binding mode of the breakthrou ...... rowth factor receptor revealed
@en
Binding mode of the breakthrou ...... rowth factor receptor revealed
@nl
P2093
P50
P3181
P1476
Binding mode of the breakthrou ...... rowth factor receptor revealed
@en
P2093
Jack U Flanagan
James M Dickson
Jeff B Smaill
Shevan Silva
P304
P3181
P356
10.1016/J.JSB.2015.10.018
P577
2015-12-01T00:00:00Z